

EMA/551845/2015

European Medicines Agency decision

P/0185/2015

of 24 August 2015

on the acceptance of a modification of an agreed paediatric investigation plan for lumacaftor / ivacaftor (EMEA-001582-PIP01-13-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0185/2015

of 24 August 2015

on the acceptance of a modification of an agreed paediatric investigation plan for lumacaftor / ivacaftor (EMA-001582-PIP01-13-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0118/2014 issued on 6 May 2014, and the decision P/0337/2014 issued on 22 December 2014,

Having regard to the application submitted by Vertex Pharmaceuticals (Europe) Ltd. on 30 March 2015 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 14 August 2015, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given, following a re-examination procedure of the Paediatric Committee's opinion according to Article 25(3) Regulation (EC) No 1901/2006, an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for lumacaftor / ivacaftor, film-coated tablet, age appropriate oral solid formulation, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Vertex Pharmaceuticals (Europe) Ltd., 86-88 Jubilee Avenue, Milton Park, OX14 4RW – Abingdon, United Kingdom.

Done at London, 24 August 2015

For the European Medicines Agency
Jordi Llinares Garcia
Head of Division (ad interim)
Human Medicines Research and Development Support
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/495577/2015
London, 14 August 2015

Final opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA-001582-PIP01-13-M03

Scope of the application

Active substance(s):

Lumacaftor / ivacaftor

Condition(s):

Treatment of cystic fibrosis

Pharmaceutical form(s):

Film-coated tablet

Age appropriate oral solid formulation

Route(s) of administration:

Oral use

Name / corporate name of the PIP applicant:

Vertex Pharmaceuticals (Europe) Ltd.

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Vertex Pharmaceuticals (Europe) Ltd. submitted to the European Medicines Agency on 30 March 2015 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0118/2014 issued on 6 May 2014, and the decision P/0337/2014 issued on 22 December 2014.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.



An Opinion was adopted by the Paediatric Committee on 19 June 2015. Vertex Pharmaceuticals (Europe) Ltd. received the Paediatric Committee Opinion on 29 June 2015.

On 17 July 2015 Vertex Pharmaceuticals (Europe) Ltd. submitted to the European Medicines Agency a written request including detailed grounds for a re-examination of the Opinion.

The re-examination procedure started on 18 July 2015.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Final Opinion

1. The Paediatric Committee, having assessed the detailed grounds for re-examination, in accordance with Article 25(3) of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report :
 - 1.1. to revise its opinion and to agree to the changes regarding the measures and the timelines of the paediatric investigation plan and the timelines of the deferral in the scope set out in the Annex I of this opinion;
 - 1.2. following re-examination, to amend the scope of the modifications of the paediatric investigation plan.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric Investigation Plan

2.1. Condition: treatment of cystic fibrosis

2.1.1. Indication(s) targeted by the PIP

Treatment of cystic fibrosis

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Age appropriate oral solid formulation

2.1.4. Measures

Area	Number of studies	Description
Quality-related studies	2	1. Development of an age-appropriate fixed-dose combination film-coated tablet for children aged 6 to less than 12 years old. 2. Development of an age appropriate oral solid formulation for children below 6 years of age.
Non-clinical studies	7	3. 6-month oral (gavage) toxicity and toxicokinetics study with lumacaftor and VRT-0995096 in rats with a 1-month recovery (VX-809-TX-012). 4. 3-month oral (gavage) toxicity and toxicokinetics study with lumacaftor, ivacaftor, and VRT-0995096 in rats with a 1-month recovery (VX-809-TX-013). 5. 12-month oral (gavage) toxicity and toxicokinetics study with lumacaftor in Beagle dogs with a 1-month recovery (VX-809-TX-014). 6. Developmental and Perinatal/Postnatal Reproduction Toxicity Study in Rats, Including a Postnatal Behavioral/Functional Evaluation (VX-809-TX-017). 7. Fertility and early embryonic development study in rats with lumacaftor and VRT-0995096 (VX-809-TX-016).

		8. Oral (gavage) dose range finding study in juvenile rats (VX-809-TX). 9. Oral (gavage) toxicity and toxicokinetics study in juvenile rats with 4-week recovery (VX-809-TX).
Clinical studies	8	10. Open-label, multi-dose study to evaluate the pharmacokinetics (PK) and safety of lumacaftor in combination with ivacaftor and their respective major circulating metabolites in subjects with Cystic Fibrosis (CF) who are homozygous for the F508del-CFTR mutation aged 6 to less than 12 years. (Study VX13-809-011 Part A). 11. Randomised, double-blind, placebo-controlled study to evaluate efficacy and safety and PK in subjects with CF homozygous for the F508del-CFTR mutation aged 6 to less than 12 years. (Study VX14-809-109). 12. Randomised, double-blind, placebo-controlled study to evaluate efficacy and safety in subjects with CF who are homozygous for the F508del-CFTR mutation aged 12 to less than 18 years (and adults). (Study VX12-809-103). 13. Randomised, double-blind, placebo-controlled study to evaluate efficacy and safety in subjects with CF who are homozygous for the F508del-CFTR mutation aged 12 to less than 18 years (and adults). (Study VX12-809-104). 14. Rollover open-label long-term safety and efficacy study in subjects with CF who are homozygous for the F508del-CFTR mutation aged 12 to less than 18 years (and adults) (Study VX12-809-105). 15. Pharmacokinetic and safety study in subjects with CF who are homozygous for the F508del-CFTR mutation aged 2 to less than 6 years (Study 15). 16. Pharmacokinetic and safety study in subjects with CF who are homozygous for the F508del-CFTR mutation from birth to less than 2 years of age (Study 16). 17. Relative bioavailability study to characterize the PK of the paediatric age appropriate formulation relative to the tablet formulation in healthy adults. 18. Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the <i>F508del-CFTR</i> Mutation (Study VX15-809-110)
Extrapolation, modelling & simulation studies	0	Not applicable.

Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By March 2020
Deferral for one or more studies contained in the paediatric investigation plan:	Yes